Aurobindo Pharma expands in Europe

Aurobindo Pharma announced that it has recently concluded a strategic deal, for acquisition of Intellectual Property & Marketing Authorizations, with TAD Italy, a generic company registered in Italy. This acquisition will give Aurobindo an access to more than 70 ready to market products which will fast track Aurobindo's entry into the Italian generic market. This strategic acquisition is expected to jump start the business for Aurobindo in Italy where the market and the regulatory procedures are considered as the one of the toughest in all EU.

"This deal will provide us with a ready local platform and will help us is immediately maximising the potential of our vast internal pipleline which is to follow in the next few months. Aurobindo has already filed 22 products for registration in Italy. During the integration process, we expect to derive maximum synergies from this acquisition by shifting the manufacturing of TAD's products to our own facilities." commented Ashish Menocha, Aurobindo's Regional VP, Europe.

Aurobindo has also acquired high profile OTC brands - Mapooro and Carmiooro from TAD as a part of this deal.

This is the Company's third acquisition in Europe, after acquiring Milpharm Ltd in UK and Pharmacin International B.V., in Netherlands. The Company believes that such acquisitions reduce the time to market and enhance the relationships in the generic value chain in addition to building a broad and formidable product portfolio.

Motilal Oswal Investment Advisors Pvt Ltd, was the advisor to the Company on the transaction.

About Aurobindo Pharma Limited
Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries. For more information, visit www.aurobindo.com.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...